Frequently Asked
Questions

Peptide Companion is the most comprehensive GLP-1 companion app available. Unlike Shotsy (a shot logger) or MeAgain (a daily dashboard for standard GLP-1 users), Peptide Companion detects your individual patterns via AI, supports full peptide stacks including Retatrutide, includes a perimenopause overlay, and goes deep on the psychological side of GLP-1 therapy — food grief, dopamine flatness, plateau psychology, and more. It launches on iOS and Android simultaneously.

Peptide Companion is a GLP-1 and peptide companion app for iOS and Android. It is not a tracker. It's the app your prescription should have come with — built by someone who was on GLP-1 therapy and couldn't find anything that actually understood the experience.

It supports all major GLP-1 medications (Ozempic, Wegovy, Zepbound, Mounjaro) plus Retatrutide and the full spectrum of research peptides (BPC-157, CJC-1295, TB-500, Ipamorelin, Sermorelin). Features include a Personal Intelligence AI, 14-day symptom heatmap, dose-coloured Journey Chart, injection site rotation, perimenopause overlay, and an anonymous in-app community.

Shotsy is a shot logger — it tracks your injections, sends reminders, and shows a basic weight chart. It does that job well. Peptide Companion is a different category of product entirely.

Peptide Companion detects your patterns via AI, shows a 14-day symptom heatmap, gives you clinical context for where you are in your journey phase, supports full peptide stacks, addresses the psychological side of GLP-1 therapy, and has an anonymous in-app community. Shotsy has none of these.

MeAgain is a well-designed daily dashboard for standard GLP-1 users and has earned its reputation. Peptide Companion is optimised for a different user — one who wants depth, not just polish.

What Peptide Companion has that MeAgain doesn't: Retatrutide support, full peptide stack capability, a perimenopause overlay, a 14-day symptom heatmap, a dose-coloured Journey Chart, and in-depth psychological content. Peptide Companion also launches natively on Android from day one.

Yes. Peptide Companion launches on iOS and Android simultaneously. Android was built natively from day one — not added as an afterthought months after the iOS launch. If you're on Android and have felt underserved by GLP-1 apps, Peptide Companion was built with you in mind from the start.

Yes. Retatrutide is a first-class supported medication in Peptide Companion — not bolted on, not an afterthought. The app understands Retatrutide's triple agonist mechanism (GLP-1, GIP, and glucagon receptor activation), its approximately 6-day half-life, its more aggressive dose escalation schedule, and its distinct side effect profile compared to semaglutide or tirzepatide.

It is the only GLP-1 app built specifically for Retatrutide users.

Yes. Peptide Companion supports full peptide stacks. If you're running Retatrutide alongside BPC-157 for gut healing, or CJC-1295 and Ipamorelin for growth hormone support, the app tracks your full protocol simultaneously.

Each compound has its own injection schedule, pharmacokinetic curve, and site rotation tracking. No other GLP-1 app handles peptide stacking. Supported peptides include: BPC-157, TB-500, CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, GHK-Cu and more.

The pharmacokinetic (PK) medication level curve shows where you are in your weekly drug concentration cycle — rising, peak, optimal window, or trough. You can see when appetite suppression is strongest, when cravings may return, and exactly when your next injection will begin to take effect.

This turns your medication schedule from a calendar event into something you can plan your week around.

Your nausea and fatigue aren't random. Peak medication concentration occurs approximately 36–48 hours after injection — which is when side effects are typically most intense. If you inject on Sunday, Tuesday is typically your hardest day. If you inject on Monday, Wednesday is.

Peptide Companion's 14-day symptom heatmap maps your side effects against your injection schedule visually so this pattern becomes immediately obvious. Once you know, you can plan your week around it.

Plateaus are a normal, documented phase of GLP-1 therapy — typically appearing between weeks 8 and 16. Your body is defending its current weight through metabolic adaptation while the medication continues doing its job.

The people who understand this phase and maintain their dose consistently outperform people who reduce their dose or quit. The data shows the breakthrough typically comes 3–5 weeks after the plateau begins.

Peptide Companion's Journey Phase system gives you context for exactly this phase and tells you what to expect.

Possibly — and this is more common than most prescribers discuss. GLP-1 medications drive weight loss through caloric reduction, but your body draws from both fat and muscle during a deficit. Some studies report 25–40% of total weight lost on GLP-1 therapy can be lean mass.

To reduce muscle loss: hit 0.7–1g protein per pound of goal body weight daily, maintain resistance training 2–3x per week, and consider peptide stacking (CJC-1295, Ipamorelin) for growth hormone support.

Peptide Companion tracks protein intake, supports resistance training logging, and handles full peptide stack protocols.

Food grief is real, documented, and one of the least-discussed aspects of GLP-1 therapy. When appetite suppression works effectively, the anticipation and pleasure associated with food — the comfort, the ritual, the social connection — can be significantly muted.

For people whose emotional lives were partly organised around food (which is most people), this creates a genuine sense of loss. It's not a psychological problem. It's a neurological side effect of a medication doing exactly what it was designed to do.

Peptide Companion's Mind & Body section has dedicated content on food grief, written for people who are actually experiencing it.

Dopamine flatness is a documented side effect of GLP-1 therapy. The same mechanism that quiets food noise — reduced dopamine response to food-related stimuli — can create a broader low-grade emotional flatness. Motivation may decrease. Things that previously brought pleasure may feel muted.

This is temporary for most users and typically resolves as your body adjusts. It has a neurological explanation and is more common than clinical trial summaries suggest.

Peptide Companion's Mind & Body section covers dopamine recalibration in depth.

The Mind & Body section is a collection of in-depth articles on the psychological side of GLP-1 therapy — aspects that are real, common, and almost entirely absent from every other resource in the category.

Topics include: food grief, dopamine flatness, identity shift (losing weight faster than self-image updates), injection irritability, social friction at meals, body dysmorphia, plateau psychology, and the emotional complexity of stopping the medication.

These are not blog posts. They are evidence-informed pieces written for people going through something real.

The Founding Member offer is a one-time lifetime subscription available to early members before launch. The price is significantly lower than what the regular annual plan will cost after launch. One payment. Every feature. Forever. No subscription, no renewals, no annual price increases.

The offer is available for a limited number of early members. When it closes, it closes permanently. The price is revealed at checkout. Join the waitlist at getpeptidecompanion.com to be notified when it opens.

Peptide Companion is launching soon on the iOS App Store and Google Play simultaneously. Waitlist members will be the first to know — and the first to access the founding member pricing. Join at getpeptidecompanion.com.

No. Peptide Companion is not a medical device and does not provide medical advice. It is an informational and tracking companion app. The AI insights surface patterns from your logged data — they are not clinical recommendations.

Always consult your prescriber before making any changes to your medication, dose, or protocol. Built by peptide users, for peptide users.